Product Name: ERK5 (217-223) pT219+pY221
Product Number: PE-04ATU01
| Size: | $US |
Peptide Name: ERK5 (217-223) pT219+pY221
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T219 and Y221 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: FM(pT)E(pY)VA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T219 and Y221 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: FM(pT)E(pY)VA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Scientific Background: ERK5 (MAPK7) is a protein-serine/threonine kinase of the CMGC group and MAPK family. It is important in controlling a cell's proliferation, differentiation, and cell survival. Phosphorylation of T219 and Y221 by MEK5 (MAP2K5) increases the phosphotransferase activity of ERK5. MEK5 is activated in response to hyperosmolarity, hydrogen peroxide, and epidermal growth factor (EGF). ERK5 may be a tumour requiring protein (TRP). Although there has been no direct linkage of ERK5 to formation of carcinomas in humans in vivo, in vitro ERK5 over-expression has been shown to increase metastasis, and ERK5 inhibition has been shown to inhibit osteosarcoma cell motility. Upregulation of the MEK5 gene has been noted in breast, prostate, and liver cancer.
© Kinexus Bioinformatics Corporation 2017